Daniel S. Lorrain
Chief Science OfficerDr. Daniel S. Lorrain, Ph.D. also known as Dan, serves as the Chief Scientific Officer of Pipeline Therapeutics Inc. He serves as Chief Science Officer at Contineum Therapeutics, Inc. since March 2018. Previously, he was VP of Biology at Inception Sciences, where he led all aspects of biology and non-clinical pharmacology, including the acquisition of the remyelination company Inception 5 by Roche pharmaceuticals. Prior to joining Inception, he was Senior Director of Pharmacology at Amira Pharmaceuticals. Notably, he led the efforts of the LPA1R program that was acquired by BMS. Prior to that, he was a Research Fellow at Merck where he contributed to early CNS drug discovery. He was a postdoctoral fellow at the University of Chicago and received a PhD in Behavioral Neuroscience from the University of Buffalo in 1997 and received a B.S. in Psychology from the State University of New York at Buffalo in 1991.
Positions
- Company NameContineum Therapeutics, Inc.Stock CodeCTNMPositionChief Science OfficerColleagues
- CNCarmine N. StengonePresident, CEO & Director
- EBEvert B. SchimmelpenninkIndependent Chairman of the Board
- PTPeter T. SloverChief Financial Officer
- TRTimothy R. WatkinsChief Medical Officer & Head of Development
- MPMorgan PaulsenSenior Manager of Accounting
- TRTodd R. BradyIndependent Director
- TATroy A. IgnelziIndependent Director
- SBSarah BoyceIndependent Director
